NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026
March 10, 2026 08:05 ET | Source: NKGen Biotech, Inc. SANTA ANA,…
NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
July 10, 2025 16:30 ET | Source: NKGen Biotech, Inc. SANTA ANA,…
